Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nathan, R. A.
Right arrow Articles by Lorber, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathan, R. A.
Right arrow Articles by Lorber, R. R.
(Chest. 1997;112:34-39.)
© 1997 American College of Chest Physicians

A Comparison of Double-Strength Beclomethasone Dipropionate (84 µg) MDI With Beclomethasone Dipropionate (42 µg) MDI in the Treatment of Asthma

Robert A. Nathan MD, FCCP1; Keith B. Nolop MD2; Francis M. Cuss MD3; and Richard R. Lorber MD2

1 From the University of Colorado Health Sciences Center, Denver
2 From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ
3 From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia

Study objective: To compare the efficacy and safety of a double-strength formulation of beclomethasone dipropionate (BDP 84) metered-dose inhaler (MDI) with that of beclomethasone dipropionate (BDP 42) MDI in the treatment of chronic asthma.

Design: A 28-day, randomized, double-blind, double-dummy, placebo-controlled, multicenter study.

Setting: Outpatient.

Patients: A total of 423 patients aged 12 to 65 years (mean range, 34 to 36 years) with moderate asthma (FEV1, 50 to 80% of predicted) who required long-term inhaled corticosteroids were enrolled.

Interventions: Patients were randomized to receive BDP 84, two oral inhalations bid (336 µg/d), BDP 42, four oral inhalations bid (336 µg/d), or placebo. A fourth treatment arm administering BDP 84, eight oral inhalations bid (HD BDP 84; 1,344 µg/d) was also included to determine whether a dose-response relationship could be demonstrated.

Measurements: Spirometry, clinical observations.

Results: The three active treatments were significantly more effective (ple0.01) than placebo at all time points in improving FEV1, the primary efficacy parameter; BDP 42 and BDP 84 were comparable to each other at every time point. Secondary pulmonary function tests (FVC, forced expiratory flow at 25 to 75% of FVC, and peak expiratory flow rate) showed similar results. All three active treatments were well tolerated. A dose response between 336 µg/d and 1,344 µg/d was demonstrated.

Conclusion: In this well-controlled 28-day study, BDP 42 and BDP 84 were shown to be comparable in efficacy and safety on a microgram-for-microgram basis.

Key Words: asthma • beclomethasone dipropionate • compliance • double-strength • high dose

Submitted on October 7, 1996
Accepted on April 11, 1997




This article has been cited by other articles:


Home page
 ChestHome page
J. W. Georgitis
The 1997 Asthma Management Guidelines and Therapeutic Issues Relating to the Treatment of Asthma
Chest, January 1, 1999; 115(1): 210 - 217.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Chest Physicians.